leadf
logo-loader
viewAnteris Technologies Ltd

Admedus Ltd to showcase CardioCel® in the U.S. to drive sales

Lee Rodne, managing director, commented: "We believe CardioCel represents a disruptive technology and we are concentrating on building awareness of our product in this market."

au_admedus_lee_rodne_headshot_358_5733d1a950ffb.jpg

Admedus Ltd (ASX:AHZ) has outlined a focus on driving sales of its lead regenerative tissue product CardioCel® in the valve repair market, and as a result the company will be attending several leading U.S. cardiovascular conferences.

These include the American Association for Thoracic Surgery (AATS) Aortic Symposium 2016 May 12-13 in New York, and the 96th AATS Annual Meeting taking place from 14 – 18 May in Baltimore, Maryland.

Lee Rodne, managing director, commented:

“CardioCel is fast becoming the surgeon-preferred material for reconstruction and repairs in the aortic and mitral valve repair market, with the product providing a genuine alternative for patients compared to bio-prosthetic valves.

"We believe CardioCel represents a disruptive technology and we are concentrating on building awareness of our product in this market."

The global market for cardiovascular disease is estimated to grow to USD $4.8 billion by 2020.

In the U.S., surgeons currently perform 106,000 heart valve operations each year.

Rodne added: “Admedus is focused on continuing to show the utility and benefits of CardioCel to patients and surgeons in the multibillion dollar heart valve market, expanding the use of CardioCel in the adult valve market and driving CardioCel sales globally.”


Next steps

Admedus continues to progress its aortic valve reconstruction post-market study with several centres globally recruiting patients.

An update on the study is anticipated in the coming months.

The study is designed to further show the use of CardioCel in repairing aortic heart valves and its potential for improved patient outcomes compared to bio-prosthetic valves.


Broker targets

New York based Maxim Group has a buy recommendation on the company and a $2.00 price target.

Hong Kong based boutique investment bank Cedrus Investments have a fair value of A$1.95 per share by December 2018.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

Quick facts: Anteris Technologies Ltd

Price: 4 AUD

ASX:AVR
Market: ASX
Market Cap: $23.64 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Anteris Technologies Ltd named herein, including the promotion by the Company of Anteris Technologies Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Admedus CEO in New York to update on recent key milestones

Admedus Ltd (ASX:AHZ) CEO Wayne Paterson visited the Proactive Investors New York studio to update on key milestones the company has achieved in the past few months, including receiving European approval on two of its products.

on 03/17/2019

2 min read